The BIVDA Market Audit Report for Q1 and Q2 2024 has been published for companies participating in the UK.
BIVDA’s Market Audit shows growth in the UK IVD market, after accounting for the reduction in COVID-19 testing. There is significant recovery in the core laboratory testing market with the exception of infectious diseases.
The total IVD market is assessed at £1.2bn, of which over 10% is glucose blood testing as recorded in published prescription data.
Market Audit participants benefit from detailed data down to individual test types – if you would like to receive this do talk to us about participation. It only requires sales data submission twice per year, and help is available if required to submit data or interpret results.
A full version of the audit is available for participant companies upon request.
